Corona Remedies hares made their debut on Dalal Street today, listing on both the NSE and the BSE. The stock was listed at a premium of 38%. The IPO – entirely an offer for sale of 0.62 crore shares – raised Rs 655.37 crores from the public.
Corona Remedies IPO: Other details
The issue price has been fixed at Rs 1,062 per share. Also, the issue included a reservation of up to 58,035 shares for employees offered at a discount of Rs 54 to the issue price.
| Corona Remedies IPO | Key Details |
| Issue price | Rs 1,062 each |
| IPO Date | December 8-10 |
| GMP | 32% |
| IPO Allotment date | December 11 |
| Listing date | December 15 |
About Corona Remedies
Corona Remedies is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas. The company’s diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
Corona Remedies Share Price Highlights
Corona Remedies IPO Listing LIVE: Shares close 2% lower to listing price
The shares of Corona Remedies on the first day of trading closed at Rs 1,438.4 on NSE, down 2.1% from its opening price but up 35% from its issue price.
On BSE, the shares of the pharma company closed at Rs 1,437.2, down 1% from its opening price but up 35% from its listing price.
Corona Remedies IPO Listing LIVE: International market expansion
CRL operates in over 20 countries, including UAE, Uzbekistan, Philippines, Kenya, and Cyprus. The company as per its RHP aims to expand its international presence by leveraging its hormone portfolio, and R&D segment. However, it would require approvals like EU GMP certification and WHO accreditations which is likely to reinforce its credibility worldwide.
Corona Remedies IPO Listing LIVE: CAGR and export market
The company is targeting revenue CAGR of 20% in the next 2-3 years by undertaking 15-20 new launches every year, Deven Choksey said in a report. As a long-term strategy, it will enter the exports market and increase its revenue contribution to 5% by FY28, it added.
Corona Remedies IPO Listing LIVE: Acquisitions and capacity expansions
As of recent the company has acquired Myoril from Sanofi, and Spye from Bayer. Further, the company aims at expanding its gynaecology and cardiology portfolio and has entered in a partnership with Ferring for Solifenacin. The company has also expanded its capacity in the Bhayla hormones facility.
Corona Remedies IPO Listing LIVE: Listing price and GMP
The shares of Corona Remedies were listed today at the stock exchange at a price of Rs 1,470. This indicates a GMP of nearly 38.5% over the upper price band of the shares. The price band for shares was set at Rs 1008-1062.
The shares were listed above the estimated GMP of Rs 1404.5, marking a positive debut for CRL's shares.
Corona Remedies IPO Listing LIVE: Industry outlook
As per the Ministry of Chemicals and Fertilisers, the Indian pharmaceuticals industry is the world’s third largest by volume and fourteenth largest by value. The Indian pharmaceutical industry was valued at approximately Rs 4.5 lakh crore (including bulk drugs and formulation exports) as of the financial year 2025. At present, low-value generics constitute a large part of India’s exports. The country accounts for approximately 3.5% of total drugs and medicines exported globally to more than 200 countries and territories, including highly regulated markets such as the US, the UK, the European Union and Canada.
Corona Remedies IPO Listing LIVE: Diversified portfolio
The company maintains a broad portfolio of 71 brands (as of June 30, 2025) spanning women’s healthcare, cardio-diabetes, pain management, urology and other therapy areas. The four targeted therapeutic segments, women’s healthcare, cardio-diabetes, pain management and urology contributed 68.26% of domestic sales for MAT June 2025, recording a robust CAGR of 22.40% between MAT June 2022 and MAT June 2025.
Corona Remedies IPO Listing LIVE: Stock performance
Corona Remedies shares made their stock market debut on the BSE today and were trading higher post listing. The stock was last seen at Rs 1,473.85 on the BSE, up Rs 21.85 or 1.50%.
Corona Remedies IPO Listing LIVE: Stock performance
Corona Remedies shares made their stock market debut on the BSE today and were trading higher post listing. The stock was last seen at Rs 1,473.85 on the BSE, up Rs 21.85 or 1.50%.
The share price of Corona Remedies is listed at Rs 1,470 on the National Stock Exchange, a premium of 38.4%. The IPO was listed at Rs 1452 on the BSE, a premium of 36.7%.
The IPO was opened for bidding on December 08 and closed on December 10. The shares of Corona Remedies met the grey market expectations.
Listing ceremony of Corona Remedies Limited will be starting soon in Ahmedabad. Watch the ceremony live!https://t.co/0T6NAB7GzV#nseindia #nse #listing #ipo #stockmarket #sharemarket #coronaremedieslimited @ashishchauhan
— NSE India (@NSEIndia) December 15, 2025
Corona Remedies IPO Listing LIVE: Growth of the company
The company is an India-focused branded pharmaceutical formulations player with a portfolio spanning women’s healthcare, cardio-diabetes, pain management, urology and select speciality segments. It has emerged as the second fastest-growing company among the top 30 Indian Pharmaceutical Market (IPM) participants between MAT June 2022 and MAT June 2025. Over this period, domestic sales recorded a CAGR of 16.77%, significantly outperforming the IPM’s CAGR of 9.21%. A key driver of this outperformance has been the company’s emphasis on new product introductions.
Corona Remedies IPO Listing LIVE: Expansion in international business
The Company is pursuing a calibrated expansion of its international footprint by leveraging its hormone portfolio, R&D capabilities, and differentiated product offerings to drive penetration in select overseas markets. Its presence spans over 20 countries, including the United Arab Emirates, Uzbekistan, the Philippines, Kenya, and Cyprus, supported by a market-specific approach that incorporates regulatory requirements, market size, competitive dynamics, and therapy-area demand. International approvals for its Indian manufacturing facilities, including EU GMP certification and WHO accreditations, enhance the Company’s ability to access regulated markets and strengthen its credibility with healthcare professionals and regulatory authorities.
Corona Remedies IPO Listing LIVE: Operates two manufacturing plants
Corona Remedies operates two manufacturing facilities located in Gujarat and Himachal Pradesh, and is currently commissioning a hormone manufacturing facility in Gujarat, which is expected to commence commercial operations in Q1 FY27. The company’s facilities support a wide range of pharmaceutical dosage and packaging forms, including tablets, capsules (both hard and soft gelatin), sachets, liquids, and drops.
Read more: Corona Remedies IPO: 10 key risks that investors can’t miss
Corona Remedies IPO Listing LIVE: Key strategy behind prescription growth
Corona Remedies’ focused strategy of engaging with specialist and super-specialist doctors has enabled the company to outpace overall prescription growth in IPM during MAT June 2022 to MAT June 2025. This strategy is supported by the targeted deployment of marketing and distribution teams across urban and semi-urban markets, which together contributed 75.11% of domestic sales in MAT June 2025.
Corona Remedies IPO Listing LIVE: Choice Broking on IPO valuation
"Recent acquisitions have strengthened its presence in key chronic segments and improved growth visibility. Corona Remedies' IPM ranking has improved from 37th to 29th, reflecting rising scale and competitiveness. While valuations appear fully priced, the company’s sustainable business model and long-term growth prospects support a 'Subscribe for Long Term' rating for this issue," said Choice Broking in an IPO note.
Corona Remedies IPO Listing LIVE: Registrar responsibilities
Link Intime has been appointed as the registrar to the IPO. The registrar is responsible for finalising the allotment, processing refunds, and ensuring shares are credited to investors’ demat accounts.
Corona Remedies IPO Listing LIVE: IPO timeline
The IPO opened for subscription on December 8, 2025, and closed on December 10. The basis of allotment was finalised on December 11, following which the refund and share credit process was initiated.
Corona Remedies IPO Listing LIVE: Business operations
Corona Remedies operates in the pharmaceutical sector, focusing on branded formulation products. Its portfolio covers therapeutic areas such as women’s health, cardio-diabetes, pain management, urology, and other multispecialty segments, with sales spread across domestic markets.
Corona Remedies IPO Listing LIVE: Lead manager to the issue
Kotak Mahindra Capital Company Limited is the lead manager for the IPO. The firm is responsible for managing the issue process, coordinating with regulators, and handling institutional investor participation during the offer period.
Corona Remedies IPO Listing LIVE: Price band and total issue size
The price band for the IPO has been fixed between Rs 1,008 - Rs 1,062 per share. Investors need to place bids within this range.
The total size of the public issue is Rs 655.37 crore, calculated at the upper end of the price band.
Corona Remedies IPO Listing LIVE: Key dates
The Corona Remedies IPO opened for bidding on December 8, 2025, and closed on December 10. The allotment was finalised on December 11, and the company’s shares are scheduled to list on the BSE and NSE today December 15.